CSIMarket Company Name, Ticker, Suppliers, else..
 
Nkgen Biotech Inc   (NASDAQ: NKGN)
Other Ticker:  
 
 
Price: $0.1355 $-0.02 -9.967%
Day's High: $0.2 Week Perf: 0.37 %
Day's Low: $ 0.14 30 Day Perf: -15.31 %
Volume (M): 295 52 Wk High: $ 2.19
Volume (M$): $ 40 52 Wk Avg: $0.69
Open: $0.20 52 Wk Low: $0.10



 Market Capitalization (Millions $) 6
 Shares Outstanding (Millions) 41
 Employees 42
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -73
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0

Nkgen Biotech Inc
Nkgen Biotech Inc is a biotechnology company that focuses on developing novel treatments for cancer and other life-threatening diseases. They specialize in utilizing natural killer (NK) cells, a type of immune cell, for therapeutic purposes. Nkgen Biotech Inc is known for its innovative research and development of NK cell-based therapies, including CAR-NK cell therapies which involve genetically modifying the NK cells to enhance their tumor-killing abilities. The company is committed to improving patient outcomes and revolutionizing the field of cancer treatment with their groundbreaking approaches.


   Company Address: 3001 Daimler Street Santa Ana 92705 CA
   Company Phone Number: 396-6830   Stock Exchange / Ticker: NASDAQ NKGN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALEC        17.61% 
FATE        17.61% 
MRNA        10.25% 
NVAX        10.25% 
SABS        18.64% 
STRO        62.16% 
• View Complete Report
   



Clinical Study

Navigating Promise and Peril NKGen Biotechs Dual Journey in FTD Treatment Innovation and Financial Realignment,

Published Fri, Feb 21 2025 5:45 PM UTC

Emerging Therapeutic Frontier: NKGen Biotech s Innovative Step Forward in Frontotemporal Dementia Treatment Amid Financial Challenges NKGen Biotech Inc., a company immersed in the cutting-edge landscape of biotechnology, has taken a meaningful stride in the pursuit of emerging therapeutic solutions with the announcement of the first dose administration of Troculeucel to a fr...
Clinical Study

Evolving Treatment NKGen Biotechs Promising Advances in Alzheimers and Solid Tumor Therapies

Published Thu, Sep 12 2024 12:06 PM UTC

Recent developments from NKGen Biotech highlight significant strides in the treatment of two major health challenges: moderate Alzheimer s disease (AD) and advanced solid tumors. The company s innovative approach, leveraging natural killer (NK) cell therapies, stands out in an increasingly competitive biotech landscape. With pivotal Phase 1 clinical data indicating potential...
Clinical Study

Pioneering Progress NKGen Biotechs Breakthroughs in NK Cell Therapies for Alzheimers and Solid Tumors

Published Tue, Jul 30 2024 12:05 PM UTC

NKGen Biotech, a forward-thinking clinical-stage biotechnology company, is making significant strides in the field of natural killer (NK) cell therapies, positioning itself as a key player in the evolving landscape of cancer treatment and neurodegenerative disease management. This article synthesizes recent advancements showcased by NKGen at notable conferences, particularly...
Clinical Study

NKGen Biotech Breaks New Ground with Allogeneic NK Cell Therapy for Solid Tumors - Driving Towards Safer, More Effect...

Published Wed, Jun 12 2024 5:05 PM UTC

NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024SANTA ANA, Calif., June 12, 2024 - NKGen Biotech, a leading clinical-stage biotechnology company specializing in the development of innovative autologous, allogeneic, and CAR-NK natural killer (NK) cell therapeutics, announce...
Clinical Study

NKGen Biotech to Present Updated Phase 1 Data on Innovative Allogeneic NK Cell Therapy for Solid Tumors at Prestigiou...

Published Mon, Jun 3 2024 12:05 PM UTC

NKGen Biotech, a clinical-stage biotechnology company, is set to present updated Phase 1 data on its SNK02 allogeneic NK cell therapy in solid tumors at the 6th Annual Allogeneic Cell Therapies Summit. The event will take place from June 10-12, 2024, in Boston, MA. This announcement marks a significant milestone for NKGen Biotech and brings hope to patients with solid tumors...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com